lifestyle.buyersdesire.org

Author: AlzeCure Pharma

Last Patient has Completed AlzeCure’s Phase Ib Clinical Study with NeuroRestore ACD856

April 20, 2026
AlzeCure Pharma Publishes its Annual Report for 2025

April 8, 2026
AlzeCure Pharma to Present at Redeye Healthcare Day on April 14

April 7, 2026
AlzeCure Pharma to Present at Redeye Alzheimer’s Theme Event on April 9

April 1, 2026
AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at the Alzheimer’s Conference AD/PD

March 19, 2026
AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm on March 11

March 13, 2026
AlzeCure Publishes its Year-End Report for January – December 2025

March 12, 2026
Pain Project ACD440 Granted Orphan Drug Status in the EU

March 11, 2026
AlzeCure Abstract on NeuroRestore ACD856 accepted at the Alzheimer’s conference AP/PD 2026

February 3, 2026
AlzeCure Pharma Selected to Present at the Bio-Neuroscience conference in Amsterdam

February 2, 2026